Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Dose-finding Study for SPM 962 in Advanced Parkinson's Disease Patients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Otsuka Pharmaceutical Co., Ltd.
ClinicalTrials.gov Identifier:
NCT01628848
First received: June 24, 2012
Last updated: February 3, 2014
Last verified: February 2014
Results First Received: February 3, 2014  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Parkinson's Disease
Interventions: Drug: SPM 962
Drug: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
SPM 962 SPM 962 transdermal patch
Placebo Placebo transdermal patch

Participant Flow:   Overall Study
    SPM 962     Placebo  
STARTED     87     87  
COMPLETED     75     73  
NOT COMPLETED     12     14  
Adverse Event                 9                 7  
Lack of Efficacy                 0                 4  
Withdrawal by Subject                 0                 2  
Physician Decision                 3                 1  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Excluded 1 sebject of each arm by vaiolation of protocol

Reporting Groups
  Description
SPM 962 SPM 962 transdermal patch
Placebo Placebo transdermal patch
Total Total of all reporting groups

Baseline Measures
    SPM 962     Placebo     Total  
Number of Participants  
[units: participants]
  86     86     172  
Age  
[units: participants]
     
<=18 years     0     0     0  
Between 18 and 65 years     24     26     50  
>=65 years     62     60     122  
Age  
[units: years]
Mean ± Standard Deviation
  67.0  ± 6.8     66.8  ± 8.3     66.9  ± 7.5  
Gender  
[units: participants]
     
Female     52     42     94  
Male     34     44     78  
Region of Enrollment  
[units: participants]
     
Japan     87     87     174  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Unified Parkinson's Disease Rating Scale (UPDRS) Part 3 Sum Score   [ Time Frame: baseline, 12 weeks after dosing ]

2.  Secondary:   UPDRS Part 2 Sum Score (Average Score of on State and Off State)   [ Time Frame: baseline, 12 weeks after dosing ]

3.  Secondary:   Off Time   [ Time Frame: baseline, 12 weeks after dosing ]

4.  Secondary:   Effective Rate in UPDRS Part 3 Sum Score   [ Time Frame: Baseline, 12 weeks after dosing ]

5.  Secondary:   UPDRS Part 1 Sum Score   [ Time Frame: Baseline, 12 weeks after dosing ]

6.  Secondary:   Effective Rate in Off Time   [ Time Frame: Baseline, 12 weeks after dosing. ]

7.  Secondary:   UPDRS Part 2 Sum Score (on State)   [ Time Frame: Baseline, 12 weeks after dosing ]

8.  Secondary:   UPDRS Part 2 Sum Score (Off State)   [ Time Frame: Baseline, 12 weeks after dosing ]

9.  Secondary:   UPDRS Part 4 Sum Score   [ Time Frame: Baseline, 12 weeks after dosing ]

10.  Secondary:   Total of UPDRS Part 2 Sum Score (Average Score of on State and Off State) and UPDRS Part 3 Sum Score   [ Time Frame: Baseline, 12 weeks after dosing ]

11.  Secondary:   Total of UPDRS Part 1 Sum Score, UPDRS Part 2 Sum Score (Average Score of on State and Off State), UPDRS Part 3 Sum Score, and UPDRS Part 4 Sum Score.   [ Time Frame: Baseline, 12 weeks after dosing ]

12.  Secondary:   The Modified Hoehn & Yahr Severity of Illness   [ Time Frame: Baseline, 12 weeks after dosing ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Director of Clinical Research and Development
Organization: Otsuka Pharmaceutical Co., Ltd.
phone: +81-3-6131-7366


No publications provided


Responsible Party: Otsuka Pharmaceutical Co., Ltd.
ClinicalTrials.gov Identifier: NCT01628848     History of Changes
Other Study ID Numbers: 243-05-001, JapicCTI-060287
Study First Received: June 24, 2012
Results First Received: February 3, 2014
Last Updated: February 3, 2014
Health Authority: Japan: Ministry of Health, Labor and Welfare